Immunofluorescence revealed the presence of RSL3 in these grafts, alongside a reduction in S100A4+FTH1+ fibroblast cells and PLIN1+α-SMA+ adipocyte cells in keloid grafts following RSL3 therapy (Figure 7J-K), consistent with in vitro experiments. The gene discussed is FTH1; the disease is keloid.